AGENUS INC. Files 8-K Report
Ticker: AGEN · Form: 8-K · Filed: Sep 23, 2025 · CIK: 1098972
Sentiment: neutral
Topics: 8-K, corporate-disclosure
TL;DR
AGENUS INC. filed an 8-K on 9/17/25 for 'Other Events'.
AI Summary
On September 17, 2025, AGENUS INC. filed an 8-K report detailing an event under 'Other Events'. The company, formerly known as ANTIGENICS INC /DE/, is incorporated in Delaware and headquartered in Lexington, Massachusetts.
Why It Matters
This filing indicates a corporate event or disclosure by AGENUS INC. that is significant enough to warrant immediate reporting to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently indicate financial distress or significant negative events.
Key Numbers
- 000-29089 — SEC File Number (Identifies the company's filing history with the SEC.)
- 06-1562417 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- AGENUS INC. (company) — Registrant
- ANTIGENICS INC /DE/ (company) — Former Company Name
- September 17, 2025 (date) — Date of earliest event reported
- Lexington, Massachusetts (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific event is AGENUS INC. reporting under 'Other Events' in this 8-K filing?
The provided text does not specify the exact nature of the 'Other Events' beyond the filing itself.
When was AGENUS INC. formerly known as ANTIGENICS INC /DE/?
The date of the name change from ANTIGENICS INC /DE/ to AGENUS INC. was November 15, 1999.
What is AGENUS INC.'s principal executive office address?
AGENUS INC.'s principal executive offices are located at 3 Forbes Road, Lexington, Massachusetts 02421.
What is the SIC code for AGENUS INC.?
The Standard Industrial Classification (SIC) code for AGENUS INC. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the fiscal year end for AGENUS INC.?
AGENUS INC.'s fiscal year ends on December 31.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-09-23 17:12:12
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
Filing Documents
- agen-20250917.htm (8-K) — 41KB
- 0001193125-25-213574.txt ( ) — 140KB
- agen-20250917.xsd (EX-101.SCH) — 23KB
- agen-20250917_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously announced on June 3, 2025, the Company and Zydus Pharmaceuticals (USA) Inc. entered agreements pursuant to which, (i) under an asset purchase agreement Zydus will acquire assets comprising the Company's manufacturing operations, (ii) under a stock purchase agreement Zydus will acquire a minority position in the Company and (iii) under a license agreement Zydus will receive certain commercial rights in India and Sri Lanka relating to intellectual property associated with BOT/BOL. The Company and Zydus jointly submitted a filing to the Committee on Foreign Investment in the United States (CFIUS) to commence the CFIUS review process. On September 17, 2025, CFIUS requested that the Company and Zydus voluntarily submit a full notice application with CFIUS related to the transactions. Based on the anticipated CFIUS review time related to the full notice filing the anticipated closing of these transactions has now shifted to the fourth quarter of 2025. More detailed descriptions of the asset purchase agreement and stock purchase agreement are contained in our Current Report on Form 8-K filed with the SEC on June 4, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 23, 2025 By: /s/ Garo H. Armen, Ph.D. Garo H. Armen, Ph.D., Chairman and CEO